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INTRODUCTION
IgA nephropathy (IgAN) was first described by Berger
and Hinglais in 1968 and is now recognized to be the most
common form of primary glomerulonephritis worldwide (1,
2). The clinical course of IgAN is variable, with some pati-
ents having stable renal function over decades and others devel-
oping hypertension, nephrotic syndrome, and chronic renal
failure (3). About 20-50% of adult patients with IgAN devel-
op progressive renal failure, but the pathogenesis remains
unknown and a treatment regimen has not been established
(4). Although children have been reported to have a more
benign prognosis for IgAN than adults, recent studies show
that IgAN in children is not an entirely benign disease (4). 
Cyclosporin A (CyA) is a potent immunosuppressive drug
that is frequently used in the therapy of various immune-medi-
ated glomerular diseases (5). Several reports have indicated
its potential role in treating IgAN with encouraging results,
such as significant reduction of proteinuria, in small random-
ized clinical trials or small uncontrolled trials (6-8). Howev-
er, the histological effects of CyA in children with IgAN have
not been reported previously. 
The aim of this study was to evaluate the clinical and his-
tological effects of CyA in children with IgAN.
MATERIALS AND METHODS
We retrospectively reviewed the charts of 14 patients (mean
age 8.9±2.9 yr; eight males, six females) with IgAN who
were treated with CyA and prednisolone from 1993 to 2001
(Table 1). Ten of the 14 children were ≤10 yr old. The medi-
an duration of follow-up was 4.6 yr (range 1.4-11 yr). All
patients underwent a renal biopsy within one or two months
before CyA therapy and a follow-up biopsy after CyA thera-
py. The glomerular changes were categorized according to
the Haas classification (9): subclass I, minimal or no mesan-
gial hypercellularity without glomerular sclerosis; subclass
II, focal and segmental glomerular sclerosis without active
cellular proliferation; subclass III, focal proliferative glomeru-
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Effects of Cyclosporin A Therapy Combined with Steroids and
Angiotensin Converting Enzyme Inhibitors on Childhood IgA
Nephropathy
To evaluate the effects of cyclosporin A (CyA) on clinical outcome and pathologic
changes in children with IgA nephropathy (IgAN), we retrospectively evaluated 14
children (mean age 8.9±2.9 yr; eight males, six females) who were treated with
CyA and steroids. The starting dose of CyA was 5 mg/kg per day, and the drug level
was maintained at 100-200 ng/mL. The mean CyA level was 183.8±48.3 ng/mL
(range 120.7-276.0 ng/mL) and the mean duration of CyA therapy was 10.9±1.9
months (range 8-12 months). After CyA therapy the mean 24 hr urinary protein excre-
tion declined from 107.1±35.1 mg/m2/hr to 7.4±2.4 mg/m2/hr (P<0.001) and serum
albumin increased from 3.3±0.6 g/dL to 4.3±0.3 g/dL (P<0.001). At a follow-up
biopsy the histological grade of IgAN was improved in seven (50%) of the 14 patients,
remained the same in three (21%), and was aggravated in four (29%). Serum cre-
atinine, creatinine clearance, and blood pressure did not differ before and after CyA
therapy. Two patients (14%) showed CyA-induced nephrotoxicity at the second biop-
sy. Our findings indicate that CyA therapy may be effective in reducing proteinuria
and regressing renal pathology in a subset of children with IgAN. 
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lonephritis; subclass IV, diffuse proliferative glomerulonephri-
tis; and subclass V, any biopsy showing ≥40% globally scle-
rotic glomeruli and/or ≥40% estimated cortical tubular atro-
phy or loss. 
Renal biopsy specimens were also scored semiquantitatively
using the modified scoring system of Andreoli et al. (10) and
Foster et al. (11). Acute changes included mesangial hyper-
cellularity (scored 0-3), mesangial matrix expansion (0-3),
interstitial mononuclear infiltrate (0-2), cellular crescents (0-
3), and basement membrane adhesion to Bowman’s capsule
(0-3). Chronic renal injury was scored by interstitial fibrosis
and tubular atrophy (0-2), fibrous crescents (0-3), and seg-
mental or global sclerosis (0-3). The sum of these scores for
acute and chronic injury constituted the activity index and
the chronicity index, respectively. Interstitial mononuclear
infiltrate, interstitial fibrosis, and tubular atrophy were com-
bined to give the tubulointerstitial (TI) scores. For immu-
nofluorescent (IF) microscopy, a portion of fresh renal tissue
was frozen and stained with fluorescein isothiocyanate (FITC)-
conjugated antibodies against human IgG, IgA, IgM, C3,
C4, and fibrinogen. The overall intensity of IF was scored
semiquantitatively, where 0=negative, 0.5=trace (+/-), 1=
mild (+), 2=moderate (++), and 3=severe (+++). We also
performed electron microscopy on the biopsy specimens to
confirm the mesangial location of the deposits. 
CyA (Cipol-N, Chong Kun Dang Pharma, Seoul, Korea)
was administered to patients with severe nephritis defined as
nephrotic syndrome, heavy proteinuria (>1 g/day), or biop-
sy specimen class III or more, except for one patient (No. 7)
who received CyA because of persistent proteinuria. The start-
ing dose of CyA was 5 mg/kg/day and the blood level was
maintained at 100-200 ng/mL. We monitored the CyA level
weekly at the beginning of treatment and thereafter every
month. The mean (±SD) CyA level was 183.8±48.3 ng/
mL (range 120.7-276 ng/mL) and the mean duration of CyA
therapy was 10.9±1.9 months (range 8-12 months). Pred-
nisolone (1-2 mg/kg/day) was given in three divided doses
for four weeks and was gradually reduced to a single dose of
5-10 mg/day on alternate days during CyA therapy. The medi-
an duration of prednisolone tapering was 3.2 yr (range 1.4-
8.5 yr). An angiotensin converting enzyme (ACE) inhibitor
(captopril or cilazapril) was concurrently used in 12 patients
(median treatment time 3.5 yr, range 1.7-5.2 yr) and calci-
um channel blocker in 10 patients (median three yr, range
1-3.7 yr). 
Clinical state at the end of CyA therapy or at the latest obser-
vation was classified as follows (12): A, normal urine and renal
function; B, microscopic hematuria without proteinuria (B1),
or proteinuria of <40 mg/m2/hr with or without hematuria
(B2); C, active renal disease with proteinuria of >40 mg/m2/hr
and GFR of ≥60 mL/min/1.73 m2; D, renal insufficiency. 
Statistical analysis was performed using the Medcalc statis-
tical package. Continuous variables were expressed as mean±
standard deviation (SD) or standard error of the mean (SEM),
or as a median with ranges. Differences between biopsy find-
ings before and after therapy were assessed by Wilcoxon’s
signed rank test. P<0.05 was considered significant.
RESULTS
Clinical characteristics of the 14 patients with IgAN are
shown in Table 1. Five patients had non-nephrotic proteinuria
(one class II, one class III, three class IV), seven had nephrot-
ic-range proteinuria (three class III, four class IV), and two
had nephrotic syndrome (class IV). Gross hematuria was pre-
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*Nephrotic syndrome.
M, male; F female; GH, gross hematuria; ACEI, angiotensin converting enzyme inhibitor; CCB, calcium channel blocker.
Clinical status 
at the end of 
therapy/at the
latest visit
Follow-up
(yr)
Length of
CCB
therapy
(yr)
Length of
ACEI
therapy
(yr)
Proteinuria
(mg/m2/hr)
before CyA
GH
Length of 
steroids
(yr)
Length of
CyA 
(months)
Proteinuria
(mg/m2/hr)
after CyA
Age (yr)/
Sex
Case
No.
1 6.2/M + 76.9 10.2 8.5 8 2 2 8.5 B1/B2
2 13.0/M + 79.6 31.1 1.4 8 - - 1.4 C/C
3 10.0/M + 103.1 2.1 3.2 8 - - 11 B1/A
4 8.0/M + 219.3 3.8 4.8 8 4.8 3 4.8 B1/B1
5 11.0/M + 94.4 5.6 4.5 12 3.7 3.7 4.5 A/C
6* 6.7/F + 508 24.8 4.8 12 4.8 3.1 7.7 B2/A
7 10.0/F + 29.2 6.9 5.2 12 5.2 3.2 8.9 B2/B2
8 7.0/F + 24.5 3.5 4.7 12 3.5 3.3 4.7 A/A
9 7.2/M - 61.4 2.7 3.2 12 4.5 3.1 4.5 B1/A
10 13.9/M - 24.6 2.7 2.0 12 3 1 6.2 B1/B2
11 9.9/M - 12.4 1.4 2.6 12 2.6 - 2.6 B1/B1
12 4.2/F + 17.6 1.5 1.7 12 1.7 1 4.2 B1/A
13 12.0/F + 56.1 5.9 3.5 12 3.5 2.5 3.5 B1/A
14* 5.9/F - 193.1 2.0 2.3 12 2.3 - 2.3 B1/B1
Table 1. Clinical data of 14 patients with severe IgA nephropathy
sent in 10 patients and one showed acute renal failure at pre-
sentation (No. 11). At the end of CyA therapy, two patients
showed normal urinalysis and renal function (state A) find-
ings, nine had microscopic hematuria without proteinuria
(state B1), two had proteinuria of <40 mg/m2/hr (state B2),
and one had active renal disease with proteinuria of >40 mg/
m2/hr (state C). At the latest follow-up, six patients showed
state A, three state B1, three state B2, and two state C (Fig.
1). CyA was well tolerated in all patients and none required
drug discontinuation or had any adverse event that warrant-
ed hospitalization.
The mean 24-hr urinary protein excretion declined from
107.1±35.1 mg/m2/hr to 7.4±2.4 mg/m2/hr (P<0.001)
(Fig. 2) and serum albumin increased from 3.3±0.6 g/dL
to 4.3±0.3 g/dL (P<0.001) after CyA therapy. Serum crea-
tinine, creatinine clearance, systolic blood pressure, and dias-
tolic blood pressure did not differ before and after CyA thera-
py (Table 2). 
Light microscopic and IF findings of the 14 patients are
shown in Table 3. At a follow-up biopsy the histological grade
of IgAN was improved in seven (50%) of the 14 patients,
remained the same in three (21%), and was aggravated in
four (29%) (pre-therapy: one class II, four class III, and nine
class IV; post-therapy: two class I, one class II, six class III,
four class IV, and one class V). Two (Nos. 9, 13) of the four
patients (Nos. 1, 7, 9, 13) who had aggravated Haas classes
also showed an improvement in clinical state at the last fol-
low-up (state B1 → A). 
The activity index decreased from 5.1±1.9 to 3.9±2.1,
but this decrease was not statistically significant (P=0.121).
The chronicity index and tubulointerstitial scores did not dif-
fer before and after CyA therapy. Two patients (14%) showed
possible CyA-induced nephrotoxicity at a second biopsy (No.
3, TI score 1 → 4; No. 5, TI score 2 → 4), but one patient
(No. 5) showed an improvement of TI score (score 1) at the
third biopsy performed eight yr later. IF analysis at the first
and second biopsy showed that mesangial IgA depositions
were reduced in seven (50%) of the 14 patients (Table 3).
DISCUSSION
IgAN is the most common form of glomerulonephritis
throughout the world and has a very heterogeneous clinical
course, leading to end-stage renal failure in 20-30% of pati-
ents over 20 yr (1-4, 13). Despite the fact that IgAN patients
with hypertension, renal insufficiency, heavy proteinuria, and
severe histological findings at presentation are at a high risk
of developing end stage renal failure (14), there is no consen-
sus for the treatment of patients with IgAN. Although not
established in clinical practice, several types of treatment,
including steroids, ACE inhibitors, cytotoxics, immunosup-
pressants, tonsillectomy, fish oil, and vitamin E, either alone
or in various combinations, have been used to modulate the
rate of progression (15). 
CyA has been used as a useful therapeutic agent in various
glomerular diseases (5). The action mechanism of CyA in these
conditions is not known, but may involve the following: 1)
immunomodulation by T-cell mediated cytokines, resulting
in restoration of glomerular basement membrane charge selec-
tivity (6, 16); 2) inhibition of vascular permeability factor
(17); or 3) non-specific alteration of renal hemodynamics,
resulting in reduction of proteinuria (18). 
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Fig. 1. Clinical state at presentation and at final visit.
Clinical state
Active renal disease
(nephrotic proteinuria)
Mild proteinuria
Isolated hematuria
Normal urinalysis
Before CyA (Initial visit) After CyA (Last visit)
Fig. 2. Urinary protein excretion before and after cyclosporin ther-
apy.
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Variables Pretherapy Posttherapy P value
Proteinuria (mg/m2/hr) 107.1±131.2 7.4±9.1 <0.0001
Albumin (g/dL) 3.3±0.6 4.3±0.3 <0.0001
Cholesterol (mg/dL) 236±85 166±27 0.003
Uric acid (mg/dL) 4.3±1.1 4.3±1.1 NS
Creatinine (mg/dL) 0.7±0.4 0.6±0.1 NS
Creatinine clearance 99±28 107±31 NS
(mL/min/1.73 m2)
Systolic blood pressure 100±15 95±10 NS
(mmHg)
Diastolic blood pressure 69±10 66±6 NS
(mmHg)
Table 2. Responses to treatment 
There have been only a few clinical trials on the use of CyA
for adults with IgAN (6, 7) and even fewer on the efficacy
of CyA in childhood IgAN (8). Furthermore, the histologi-
cal effect of CyA on childhood IgAN has not been reported
previously. 
The first randomized prospective single-blind study of CyA
in adults with IgAN indicated that short term CyA therapy
was beneficial in reducing proteinuria in some patients with
IgAN, but transient renal impairment was observed despite
maintaining CyA concentrations within a narrow therapeu-
tic range (6). Therefore, the authors concluded that indiscrim-
inate use of CyA in IgAN should be discouraged. 
Another study also demonstrated that CyA significantly
reduced moderate to high proteinuria with a much lower
decrease of GFR in six adults (four males, two females; aged
21-31 yr) with IgAN and proteinuria >3.5 g/day that did
not respond to corticosteroids (7). The authors speculated that
the significant decrease in the proteinuria/GFR ratio strong-
ly suggests some non-hemodynamic mechanism of CyA action.
In one of the few studies on the use of CyA in young children
with IgAN, we previously demonstrated a beneficial effect
of CyA on relapsing nephrotic syndrome associated with IgAN
in two children (8).
Although CyA did not cause histological changes in ddY
mice, an animal model of IgAN (19), the current study show-
ed that CyA therapy was effective in regressing renal histo-
logic changes in a subset of patients (about 50%) with IgAN.
Allen et al. (20) also found that CyA suppressed IgA produc-
tion by peripheral blood mononuclear cells from patients with
IgAN, and Lai et al. (6) demonstrated that serum IgA con-
centrations were reduced after CyA therapy in seven of 19
patients with IgAN. Our rationale for using CyA in child-
hood IgAN was that these immunosuppressive drugs might
reduce IgA production, and thus alleviate the abnormal im-
mune response and inflammatory reactions to IgA-mediat-
ed immune deposits. However, the concurrent use of steroids
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AI, activity index; CI, chronicity index; TI, tubulointerstitial scores.
Biopsies
Interval (mo) No.
Case
No.
Light microscopy findings
Hass classAI CI TI
Immunofluorescence findings
FibrinogenIgG IgA IgM C4C3
1 1 9 3 0 0 III - +++ - +/- - +
2 6 2 0 IV - + +/- + - +/-
2 1 12 7 2 2 IV - ++ +/- + - +/-
2 4 2 2 III - ++ +/- + - +
3 1 8 2 2 1 III +/- + +/- +/- +/- +
2 2 2 4 I ++ +++ - - - -
4 1 9 5 1 2 IV - ++ - ++ ++ -
2 4 1 2 III +/- + +/- +/- - -
5 1 12 7 1 2 IV - +++ +++ +/- +/- -
2 96 7 4 4 IV - + +/- +/- +/- +/-
3 2 1 1 III +/- +/- - +/- - -
6 1 12 7 0 0 IV +/- ++ - + - +
2 7 1 2 IV - + - - - +/-
7 1 18 3 3 2 II - + +/- - +/- -
2 3 2 2 III - + +/- - - -
8 1 22 8 1 1 IV + ++ + + - +/-
2 2 2 0 II +/- - - - - -
9 1 13 6 1 1 IV + ++ - + - +
2 19 7 5 4 V +/- ++ - - - ++
3 3 1 2 III +/- + +/- - - +
10 1 12 5 1 2 IV +/- + - +/- - +/-
2 3 0 0 III + + +/- +/- - +/-
11 1 13 5 1 2 III - + - +/- - -
2 2 2 1 III ++ ++ - + - -
12 1 12 4 0 0 IV - ++ - - - -
2 1 0 0 I - + - - - -
13 1 25 3 1 2 III - + - +/- - +
2 5 1 1 IV - ++ - + - +
14 1 13 6 0 0 IV - ++ + - - +
2 2 1 1 III +/- + + +/- - +
Table 3. Histological data of 14 patients with severe IgA nephropathy 
or ACE inhibitor might also play a role in reducing the degree
of proteinuria in our patients (21-23). Recently, Yoshikawa
et al. (22) confirmed the beneficial effect of steroids on child-
hood IgAN and an European placebo-controlled, random-
ized trial of ACE inhibitor showed that treatment with ACE
inhibitor was an independent predictor of prognosis in chil-
dren and young people with IgA nephropathy and moderate
proteinuria (23). We also used calcium channel blockers for
their additional renoprotective effects beyond lowering blood
pressure (24). Therefore, we cannot conclude that the histo-
logical regression of IgAN observed in our study was due only
to CyA therapy. 
Although there were no serious complications of CyA ther-
apy during the period of study, two patients had chronic CyA-
induced nephrotoxicity at a second biopsy. Therefore, it is
important to use the lowest effective dosage of CyA and to
monitor the CyA level closely. In addition, this study has the
following limitations: small sample size, retrospective study
design, lack of a control group receiving steroids or ACE inhi-
bitor alone, and the relatively short length of treatment and
follow-up.
In conclusion, our study is the first systematic analysis of
CyA use in childhood IgAN and suggests that CyA combined
with steroids and ACE inhibitor may be effective in reduc-
ing proteinuria and attenuating histologic progression in a
proportion of children with IgAN. 
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